PerkinElmer logo
PerkinElmer PKI

Annual report 2025
added 02-24-2026

report update icon

PerkinElmer Balance Sheet 2011-2026 | PKI

Annual Balance Sheet PerkinElmer

2025 2024 2023 2021 2020 2019 2018 2017 2016 2015 2014 2013 2012 2011

Net Debt

2.3 B 1.99 B 2.99 B 1.21 B - 1.88 B 1.73 B 687 M 775 M - 878 M 762 M 803 M 6.2 M

Long Term Debt

2.63 B 3.15 B 3.18 B 4.98 B 1.61 B - 2.06 B 1.88 B 1.05 B 1.01 B - 1.05 B 932 M 945 M 424 M

Long Term Debt Current

589 M 242 K 722 M - - - - - - - - - - - -

Total Non Current Liabilities

- - - - - - 2.96 B 2.62 B 1.52 B 1.49 B - 1.49 B 1.35 B 1.39 B 768 M

Total Current Liabilities

1.33 B 653 M 1.45 B 1.21 B 1.65 B - 763 M 772 M 951 M 561 M - 597 M 603 M 581 M 515 M

Total Liabilities

4.92 B 4.73 B 5.69 B 7.86 B 4.22 B - 3.72 B 3.39 B 2.12 B 2.06 B - 2.09 B 1.95 B 1.99 B 1.28 B

Deferred Revenue

160 M 140 M 136 M 138 M 204 M - - - - - - - - - -

Retained Earnings

6.05 B 5.85 B 5.61 B 4.42 B 3.51 B - 2.81 B 2.6 B 2.12 B 1.99 B - 1.81 B 1.68 B 1.51 B 1.64 B

Total Assets

12.2 B 12.4 B 13.6 B 15 B 7.96 B - 6.54 B 5.98 B 4.28 B 4.17 B - 4.13 B 3.95 B 3.83 B 3.21 B

Cash and Cash Equivalents

920 M 1.16 B 913 M 603 M 387 M - 192 M 163 M 202 M 238 M - 175 M 173 M 171 M 420 M

Book Value

7.25 B 7.67 B 7.87 B 7.14 B 3.74 B - 2.81 B 2.58 B 2.15 B 2.11 B - 2.04 B 1.99 B 1.84 B 1.93 B

Total Shareholders Equity

7.25 B 7.67 B 7.87 B 7.14 B 3.74 B - 2.81 B 2.58 B 2.5 B 2.11 B - 2.04 B 1.99 B 1.94 B 1.93 B

All numbers in USD currency

Quarterly Balance Sheet PerkinElmer

2025-Q3 2025-Q2 2025-Q1 2024-Q4 2024-Q3 2024-Q2 2024-Q1 2023-Q4 2023-Q3 2023-Q2 2023-Q1 2022-Q4 2022-Q3 2022-Q2 2022-Q1 2021-Q4 2021-Q3 2021-Q2 2021-Q1 2020-Q4 2020-Q3 2020-Q2 2020-Q1 2019-Q4 2019-Q3 2019-Q2 2019-Q1 2018-Q4 2018-Q3 2018-Q2 2018-Q1 2017-Q4 2017-Q3 2017-Q2 2017-Q1 2016-Q4 2016-Q3 2016-Q2 2016-Q1 2015-Q4 2015-Q3 2015-Q2 2015-Q1 2014-Q4 2014-Q3 2014-Q2 2014-Q1 2013-Q4 2013-Q3 2013-Q2 2013-Q1 2012-Q4 2012-Q3 2012-Q2 2012-Q1 2011-Q4 2011-Q3 2011-Q2 2011-Q1

Long Term Debt

2.63 B 3.21 B 3.17 B 3.15 B 3.19 B 3.16 B 3.16 B 3.18 B 3.15 B 3.88 B 3.88 B 3.92 B 3.9 B 4.48 B 4.86 B 1.61 B 5.1 B 2.35 B 2.22 B - 1.49 B 1.62 B 2.01 B 2.06 B 2.06 B 2.06 B 2.06 B 1.88 B 1.88 B 1.88 B 1.88 B 1.79 B 1.79 B 1.79 B 1.79 B 1.01 B 1.13 B 1.06 B 1.12 B - 1.03 B 986 M 1.01 B 1.05 B 1.05 B 1.05 B 1.05 B 932 M 932 M 932 M 932 M 939 M 939 M 939 M 939 M 424 M 150 M 671 M 514 M

Total Liabilities

4.76 B 4.81 B 4.72 B 4.73 B 4.85 B 5.55 B 5.59 B 5.69 B 5.73 B 6.35 B 6.6 B 6.75 B 6.76 B 7.02 B 7.66 B 4.22 B 7.94 B 4.5 B 4.76 B - 3.63 B 3.67 B 3.62 B 3.72 B 3.72 B 3.72 B 3.72 B 3.39 B 3.39 B 3.39 B 3.39 B 3.59 B 3.59 B 3.59 B 3.59 B 2.06 B 2.17 B 2.11 B 2.16 B - 1.98 B 1.96 B 1.97 B 2.09 B 2.09 B 2.09 B 2.09 B 1.95 B 1.95 B 1.95 B 1.95 B 1.96 B 1.96 B 1.96 B 1.96 B 1.28 B 1.46 B 1.64 B 1.4 B

Deferred Revenue

- - - - 20 M 20.4 M 22.7 M 22.5 M 24.3 M 19.8 M 22 M 30.1 M 34.2 M 50.9 M 172 M 206 M 210 M 231 M 221 M - 35 M 35.1 M 32.1 M 164 M 29.9 M 29.9 M 29.9 M 155 M 30.8 M 30.8 M 30.8 M 160 M - - - 163 M - - - - - - - 169 M - - - 165 M - - - 154 M - - - 96.5 M - - -

Retained Earnings

5.96 B 5.93 B 5.88 B 5.85 B 5.76 B 5.67 B 5.63 B 5.61 B 5.54 B 5.54 B 5.51 B 4.95 B 4.83 B 4.76 B 4.59 B 3.51 B 4.24 B 4.12 B 3.88 B - 3.13 B 2.97 B 2.84 B 2.81 B 2.81 B 2.81 B 2.81 B 2.6 B 2.6 B 2.6 B 2.6 B 2.38 B 2.38 B 2.38 B 2.38 B 1.99 B 2.06 B 2.01 B 1.95 B - 1.93 B 1.88 B 1.84 B 1.81 B 1.81 B 1.81 B 1.81 B 1.68 B 1.68 B 1.68 B 1.68 B 1.55 B 1.55 B 1.55 B 1.55 B 1.53 B 1.7 B 1.68 B 1.66 B

Total Assets

12.1 B 12.4 B 12.4 B 12.4 B 12.8 B 13.4 B 13.4 B 13.6 B 13.4 B 14.2 B 14.6 B 14.1 B 13.8 B 14.2 B 14.8 B 7.96 B 14.9 B 8.74 B 8.76 B - 6.87 B 6.64 B 6.38 B 6.54 B 6.54 B 6.54 B 6.54 B 5.98 B 5.98 B 5.98 B 5.98 B 6.09 B 6.09 B 6.09 B 6.09 B 4.17 B 4.3 B 4.19 B 4.21 B - 4.03 B 4.08 B 4.03 B 4.13 B 4.13 B 4.13 B 4.13 B 3.95 B 3.95 B 3.95 B 3.95 B 3.9 B 3.9 B 3.9 B 3.9 B 3.21 B 3.4 B 3.6 B 3.31 B

Cash and Cash Equivalents

931 M 992 M 1.14 B 1.16 B 1.23 B 1.25 B 998 M 913 M 1.14 B 1.33 B 2.27 B 454 M 401 M 346 M 655 M 403 M 472 M 573 M 988 M - 258 M 219 M 195 M 192 M 192 M 192 M 192 M 163 M 163 M 163 M 163 M 202 M 202 M 202 M 202 M 238 M 312 M 248 M 211 M - 195 M 192 M 169 M 175 M 175 M 175 M 175 M 175 M 173 M 173 M 173 M 173 M 171 M 171 M 171 M 420 M 248 M 395 M 416 M

Book Value

7.38 B 7.56 B 7.64 B 7.67 B 7.92 B 7.87 B 7.85 B 7.87 B 7.69 B 7.87 B 8.03 B 7.38 B 7.07 B 7.17 B 7.19 B 3.74 B 6.96 B 4.24 B 4 B - 3.23 B 2.97 B 2.76 B 2.81 B 2.81 B 2.81 B 2.81 B 2.58 B 2.58 B 2.58 B 2.58 B 2.5 B 2.5 B 2.5 B 2.5 B 2.11 B 2.14 B 2.09 B 2.05 B - 2.05 B 2.12 B 2.06 B 2.04 B 2.04 B 2.04 B 2.04 B 1.99 B 1.99 B 1.99 B 1.99 B 1.94 B 1.94 B 1.94 B 1.94 B 1.93 B 1.95 B 1.96 B 1.91 B

Total Shareholders Equity

7.38 B 7.56 B 7.64 B 7.67 B 7.92 B 7.87 B 7.85 B 7.87 B 7.69 B 7.87 B 8.03 B 7.38 B 7.07 B 7.17 B 7.19 B 3.74 B 6.96 B 4.24 B 4 B - 3.23 B 2.97 B 2.76 B 2.81 B 2.81 B 2.81 B 2.81 B 2.58 B 2.58 B 2.58 B 2.58 B 2.5 B 2.5 B 2.5 B 2.5 B 2.11 B 2.14 B 2.09 B 2.05 B - 2.05 B 2.12 B 2.06 B 2.04 B 2.04 B 2.04 B 2.04 B 1.99 B 1.99 B 1.99 B 1.99 B 1.94 B 1.94 B 1.94 B 1.94 B 1.93 B 1.95 B 1.96 B 1.91 B

All numbers in USD currency

Balance Sheet is a fundamental financial report of PerkinElmer, providing a complete picture of the company’s financial position at a specific point in time. Unlike the income statement, which records the results of operations over a certain period, the balance sheet shows what assets the company owns, what liabilities it has to creditors, and what equity is available to the owners.

For an investor, the balance sheet is important because it allows assessing the company’s financial stability, understanding how much debt it carries, and how dependent it is on borrowed financing. It helps calculate key liquidity and leverage ratios. When analyzing, attention should be paid to the debt-to-equity ratio (Debt/Equity), the amount of cash on the balance sheet, and the ratio of current liabilities to liquid assets.

Features of balance sheet analysis
  • Vertical and horizontal analysis
    Vertical analysis shows the structure of the balance sheet as a percentage of total assets or liabilities, while horizontal analysis shows the dynamics of changes over multiple periods.
  • Asset quality
    It is important to evaluate not only the amount of assets but also their liquidity and realizability.
  • Accounting for off-balance sheet liabilities
    Some liabilities may not be directly reflected in the balance sheet, which requires additional attention.

Balance sheet of other industry stocks – Diagnostics research

Issuer Price % 24h Market Cap Country
Centogene N.V. Centogene N.V.
CNTG
- -6.23 % $ 30.6 M germanyGermany
Agilent Technologies Agilent Technologies
A
$ 111.3 -3.12 % $ 33.8 B usaUSA
Akumin Akumin
AKU
- -17.87 % $ 25.9 M canadaCanada
Biocept Biocept
BIOC
- -13.05 % $ 7.29 M usaUSA
Aspira Women's Health Aspira Women's Health
AWH
- -6.19 % $ 10.5 M usaUSA
Accelerate Diagnostics Accelerate Diagnostics
AXDX
- -61.36 % $ 2.46 M usaUSA
Koninklijke Philips N.V. Koninklijke Philips N.V.
PHG
$ 25.58 -5.68 % $ 20 B niderlandNiderland
CareDx, Inc CareDx, Inc
CDNA
$ 20.8 -5.07 % $ 1.11 B usaUSA
Chembio Diagnostics Chembio Diagnostics
CEMI
- 0.22 % $ 16.8 M usaUSA
Oxford Immunotec Global PLC Oxford Immunotec Global PLC
OXFD
- - $ 562 M britainBritain
Check-Cap Ltd. Check-Cap Ltd.
CHEK
- - $ 9.42 M israelIsrael
Co-Diagnostics Co-Diagnostics
CODX
$ 1.53 -6.13 % $ 2.04 M usaUSA
Castle Biosciences Castle Biosciences
CSTL
$ 24.24 -1.86 % $ 673 M usaUSA
DermTech DermTech
DMTK
- -11.32 % $ 2.94 M usaUSA
Global Cord Blood Corporation Global Cord Blood Corporation
CO
- - $ 399 M chinaChina
Fluidigm Corporation Fluidigm Corporation
FLDM
- 1.08 % $ 308 M usaUSA
Genetic Technologies Limited Genetic Technologies Limited
GENE
- - $ 7.1 B australiaAustralia
Genetron Holdings Limited Genetron Holdings Limited
GTH
- 0.12 % $ 80.1 M chinaChina
Charles River Laboratories International Charles River Laboratories International
CRL
$ 163.84 -1.77 % $ 8.12 B usaUSA
PRA Health Sciences, Inc. PRA Health Sciences, Inc.
PRAH
- - $ 10.7 B usaUSA
Enzo Biochem Enzo Biochem
ENZ
- -8.98 % $ 14.8 K usaUSA
Exact Sciences Corporation Exact Sciences Corporation
EXAS
- - $ 19.8 B usaUSA
Guardant Health Guardant Health
GH
$ 83.41 0.35 % $ 10.5 B usaUSA
Fulgent Genetics Fulgent Genetics
FLGT
$ 14.8 -3.27 % $ 447 M usaUSA
Heska Corporation Heska Corporation
HSKA
- - $ 1.31 B usaUSA
HTG Molecular Diagnostics HTG Molecular Diagnostics
HTGM
- -20.0 % $ 1.06 M usaUSA
Interpace Biosciences Interpace Biosciences
IDXG
$ 1.99 2.9 % $ 8.8 M usaUSA
Illumina Illumina
ILMN
$ 120.37 -5.16 % $ 19.1 B usaUSA
QIAGEN N.V. QIAGEN N.V.
QGEN
- - $ 10.6 B niderlandNiderland
Biomerica Biomerica
BMRA
$ 2.16 -1.22 % $ 4.96 M usaUSA
Lantheus Holdings Lantheus Holdings
LNTH
$ 81.17 -2.85 % $ 5.48 B usaUSA
ICON Public Limited Company ICON Public Limited Company
ICLR
$ 116.17 13.35 % $ 9.58 B irlandaIrlanda
Laboratory Corporation of America Holdings Laboratory Corporation of America Holdings
LH
$ 257.14 -0.94 % $ 21.4 B usaUSA
Medpace Holdings Medpace Holdings
MEDP
$ 413.59 0.93 % $ 11.9 B usaUSA
Celcuity Celcuity
CELC
$ 119.0 -0.89 % $ 5.56 B usaUSA
Motus GI Holdings Motus GI Holdings
MOTS
- -34.28 % $ 263 K israelIsrael
NeoGenomics NeoGenomics
NEO
$ 8.96 -0.67 % $ 1.15 B usaUSA
Neogen Corporation Neogen Corporation
NEOG
$ 9.01 -3.53 % $ 1.95 B usaUSA
National Research Corporation National Research Corporation
NRC
$ 16.54 -1.78 % $ 370 M usaUSA
Invitae Corporation Invitae Corporation
NVTA
- - $ 21.2 M usaUSA
Myriad Genetics Myriad Genetics
MYGN
$ 4.68 -3.31 % $ 433 M usaUSA
OpGen OpGen
OPGN
- -16.95 % $ 1.54 M usaUSA
Natera Natera
NTRA
$ 194.75 -2.71 % $ 19.2 B usaUSA
Quest Diagnostics Incorporated Quest Diagnostics Incorporated
DGX
$ 189.32 -2.94 % $ 21 B usaUSA
Burning Rock Biotech Limited Burning Rock Biotech Limited
BNR
$ 16.24 -2.46 % $ 175 M chinaChina
Organovo Holdings Organovo Holdings
ONVO
- -2.3 % $ 19.4 M usaUSA
Personalis Personalis
PSNL
$ 5.04 -8.36 % $ 299 M usaUSA
Precipio Precipio
PRPO
$ 29.94 -5.73 % $ 48.1 M usaUSA
Exagen Exagen
XGN
$ 2.76 1.1 % $ 59.5 M usaUSA